Desloratadine therapy for symptoms associated with perennial allergic rhinitis

Kim, Kenneth; Sussman, Gordon; Hébert, Jacques; Lumry, William R.; Lutsky, Barry N.; Gates, Davis

doi:10.1016/s1081-1206(10)60914-3

Cited by 42 publications

(33 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,25 In patients with AR subjected to nasal challenge, DL promoted significant improvement in nasal flow and symptom score, when compared with a placebo. [26][27][28] Antiallergic and anti-inflammatory effects have been described in vitro 29 33 improving all nasal symptoms including obstruction, 31,32 associated non-nasal symptoms 32 and quality of life. 31 In multicenter, randomized, doubleblind, placebo-controlled trials undertaken with adults with chronic idiopathic urticaria, DL (5 mg/day) was able to improve, to a significant extent, patients symptoms and their quality of life.…”

Section: More Recent Antihistaminesmentioning

confidence: 99%

“…36 This is a welltolerated compound, with a minimal incidence of adverse effects that is comparable with placebo. [31][32][33]36 Desloratadine does not induce clinically relevant alterations to the QTc interval, 34,36 even in individuals given drugs that employ the same hepatic metabolism route. 22,23 Despite its potential for interaction with muscarinic receptors, no significant anticholinergic effects have been reported.…”

Section: More Recent Antihistaminesmentioning

confidence: 99%

See 1 more Smart Citation

Novos anti-histamínicos: uma visão crítica

Camelo-Nunes¹

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To perform a critical evaluation of the more recent H1 antihistamines and the various terms used to describe them, based on a review of evidence on their role in the treatment of allergic disorders.Sources: Original articles, reviews and consensus documents published from 1998 to 2006 and indexed in the MEDLINE and PubMed databases. Keyword: antihistamines.Summary of the findings: Second-generation antihistamines differ from first-generation ones because of their elevated specificity and affinity for peripheral H1 receptors and because of their lower penetration of the central nervous system (CNS), having fewer sedative effects as a result. Whilst second-generation antihistamines are in general better tolerated than their predecessors, some adverse effects, principally cardiotoxicity, have been observed with some of them. Over the last 20 years, new compounds with different pharmacokinetic properties have been synthesized. The majority of these exhibit anti-inflammatory properties that are independent of their action on the H1 receptor. More recent improvements, generally in the form of active metabolites, led to the use of the term third-generation antihistamines. This term emerged spontaneously, with no clear definition of its meaning or clinical implications, creating great confusion among healthcare professionals.Conclusions: On the basis of the evidence on H1 antihistamines, none of them deserve the title third-generation antihistamine. As the Consensus Group on New Generation Antihistamines concluded, to merit this definition, a new class of antihistamines would have to demonstrate distinct clinical advantages over existing compounds and fulfill at least three prerequisites: they should be free from cardiotoxicity, drug interactions and effects on the CNS. J Pediatr (Rio J). 2006;82(5 Suppl):S173-80: Antihistamines, desloratadine, fexofenadine, levocetirizine, rupatadine.

show abstract

Section: More Recent Antihistaminesmentioning

confidence: 99%

Section: More Recent Antihistaminesmentioning

confidence: 99%

Novos anti-histamínicos: uma visão crítica

Camelo-Nunes¹

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

show abstract

“…Estudos clínicos duplo-cegos, controlados por placebo, em adultos e crianças maiores de 12 anos, indicam que a DL (5 mg/dia) é eficaz no tratamento da RA sazonal 26,31 e perene 32 e da RA intermitente 33 , melhorando todos os sintomas nasais, inclusive a obstrução 31,32 , os sintomas não nasais associados 32 e a qualidade de vida 31 . Em estudos multicêntricos, randomizados, duplo-cegos, controlados por placebo, realizados em adultos com urticária crônica idiopática, a DL (5 mg/dia) foi capaz de melhorar de forma significativa tanto os sintomas quanto a qualidade de vida dos pacientes 34,35 .…”

Section: Os Anti-histamínicos Mais Recentesunclassified

“…Tratase de um composto bem tolerado, com mínima incidência de efeitos adversos, comparáveis ao placebo [31][32][33]36 .…”

Section: Os Anti-histamínicos Mais Recentesunclassified

New antihistamines: a critical view

Camelo-Nunes¹

2006

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objective: To perform a critical evaluation of the more recent H1 antihistamines and the various terms used to describe them, based on a review of evidence on their role in the treatment of allergic disorders.Sources: Original articles, reviews and consensus documents published from 1998 to 2006 and indexed in the MEDLINE and PubMed databases. Keyword: antihistamines.Summary of the findings: Second-generation antihistamines differ from first-generation ones because of their elevated specificity and affinity for peripheral H1 receptors and because of their lower penetration of the central nervous system (CNS), having fewer sedative effects as a result. Whilst second-generation antihistamines are in general better tolerated than their predecessors, some adverse effects, principally cardiotoxicity, have been observed with some of them. Over the last 20 years, new compounds with different pharmacokinetic properties have been synthesized. The majority of these exhibit antiinflammatory properties that are independent of their action on the H1 receptor. More recent improvements, generally in the form of active metabolites, led to the use of the term third-generation antihistamines. This term emerged spontaneously, with no clear definition of its meaning or clinical implications, creating great confusion among healthcare professionals. Conclusions:On the basis of the evidence on H1 antihistamines, none of them deserve the title third-generation antihistamine. As the Consensus Group on New Generation Antihistamines concluded, to merit this definition, a new class of antihistamines would have to demonstrate distinct clinical advantages over existing compounds and fulfill at least three prerequisites: they should be free from cardiotoxicity, drug interactions and effects on the CNS. J Pediatr (Rio J). 2006;82(5 Suppl):S173-80: Antihistamines, desloratadine, fexofenadine, levocetirizine, rupatadine. ResumoObjetivo: Avaliar criticamente os mais novos anti-histamínicos anti-H1 e os diferentes termos utilizados para denominá-los, com base na revisão de evidências sobre o papel dos anti-H1 no tratamento das doenças alérgicas.Fontes dos dados: Artigos originais, revisões e consensos indexados nos bancos de dados MEDLINE e PUBMED de 1998 a 2006. Palavra chave: anti-histamínicos.

show abstract

“…Also, the newer second-generation antihistaminics have rapid onset of action, are highly effective on symptoms such as rhinorrhoea, sneezing, and nasal pruritis, and are relatively safe [11]. Levocetirizine and desloratadine are now commonly prescribed newer non-sedating second generation antihistaminics, highly selective for histamine H 1 -receptors, and are highly effective in controlling the symptoms of AR, without causing much adverse effects at therapeutic doses, as shown by several studies [12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

To Compare the Safety, Efficacy and Quality of Life in Patients with Allergic Rhinitis Treated with Levocetirizine and Desloratadine

Singh¹

2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Background: Allergic Rhinitis (AR) is a very common disease that affects almost 10-30% of the world's population. Second-generation H 1 antihistaminics are the preferred drugs for treatment of patients with AR. Levocetirizine and desloratadine are commonly prescribed newer non-sedating second-generation antihistaminics. Various studies show no difference in efficacy and quality of life (QOL) between the two drugs desloratadine and levocetirizine and that the drugs are quiet safe; however, some studies show negative impact on patients' QOL with these drugs. Studies comparing the two drugs were insufficient in India; hence, this study was designed to evaluate and compare the efficacy, safety and QOL of patients with AR, following treatment with levocetirizine or desloratadine, in the Indian scenario.

show abstract

Desloratadine therapy for symptoms associated with perennial allergic rhinitis

Cited by 42 publications

References 14 publications

Novos anti-histamínicos: uma visão crítica

Novos anti-histamínicos: uma visão crítica

New antihistamines: a critical view

To Compare the Safety, Efficacy and Quality of Life in Patients with Allergic Rhinitis Treated with Levocetirizine and Desloratadine

Contact Info

Product

Resources

About